Mode of action of fluoroquinolones

Drugs

Volumn 58, Issue SUPPL. 2, 1999, Pages 6-10

  Hooper, David C ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL DNA; CLINAFLOXACIN; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE IV; DOUBLE STRANDED DNA; ENOXACIN; NORFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UNCLASSIFIED DRUG;

ANTIBIOTIC SENSITIVITY; BINDING SITE; CELL DEATH; CONFERENCE PAPER; CRYSTAL STRUCTURE; DNA CLEAVAGE; DNA REPLICATION; DNA STRAND BREAKAGE; DNA SYNTHESIS INHIBITION; DRUG DNA BINDING; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG TARGETING; ENZYME SUBUNIT; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; NONHUMAN; SEQUENCE HOMOLOGY; X RAY CRYSTALLOGRAPHY;

ANTI-INFECTIVE AGENTS; BACTERIA; DNA TOPOISOMERASES, TYPE I; DNA-DIRECTED RNA POLYMERASES; ENZYME INHIBITORS; FLUOROQUINOLONES;

BACTERIA (MICROORGANISMS); NEGIBACTERIA; POSIBACTERIA;

EID: 0032705719     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199958002-00002     Document Type: Conference Paper

References (38)

1. Hane MW, Wood TH. Escherichia coli K-12 mutants resistant to nalidixic acid: genetic mapping and dominance studies. J Bacteriol 1969; 99: 238-41
2. Yoshida H, Kojima T, Yamagishi J, et al. Quinolone-resistant mutations of the gyrA gene of Escherichia coli. Mol Gen Genet 1988; 211: 1-7
3. Nakamura S, Nakamura M, Kojima T, et al. gyrA and gyrB mutations in quinolone-resistant strains of Escherichia coli. Antimicrob Agents Chemother 1989; 33: 254-5
4. Kato J, Nishimura Y, Imamura R, et al. New topoisomerase essential for chromosome segregation in E. coli. Cell 1990; 63: 393-404
5. Hoshino K, Kitamura A, Morrissey I, et al. Comparison of inhibition of Escherichia coli topoisomerase IV by quinolones with DNA gyrase inhibition. Antimicrob Agents Chemother 1994; 38: 2623-7
6. Ferrero L, Cameron B, Crouzet J. Analysis of gyrA and grlA mutations in step wise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus. Antimicrob Agents Chemother 1995; 39: 1554-8
7. Ferrero L, Cameron B, Manse B, et al. Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones. Mol Microbiol 1994; 13: 641-53
8. Ng EY, Trucksis M, Hooper DC. Quinolone resistance mutations in topoisomerase IV: relationship of flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase the secondary target of fluoroquinolones in Staphylococcus aureus. Antimicrob Agents Chemother 1996; 40: 1881-8
9. Khodursky AB, Zechiedrich EL, Cozzarelli NR. Topoisomerase IV is a target of quinolones in Escherichia coli. Proc Natl Acad Sci USA 1995; 92: 11801-5
10. Breines DM, Ouabdesselam S, Ng EY, et al. Quinolone resistance locus nfxD of Escherichia coli is a mutant allele of parE gene encoding a subunit of topoisomerase IV. Antimicrob Agents Chemother 1997; 41: 175-9
11. Soussy CJ, Wolfson JS, Ng EY, et al. Limitations of plasmid complementation test for determination of quinolone resistance due to changes in the gyrase A protein and identification of conditional quinolone resistance locus. Antimicrob Agents Chemother 1993; 37: 2588-92
12. Hooper DC. Mechanisms of quinolone resistance. Drug Resistance Updates 1999; 2: 38-55
13. Fournier B, Hooper DC. Mutations in topoisomerase IV and DNA gyrase of Staphylococcus aureus: Novel pleiotropic effects on quinolone and coumarin activity. Antimicrob Agents Chemother 1998; 42: 121-8
14. Blanche F, Cameron B, Bernard FX, et al. Differential behaviors of Staphylococcus aureus and Escherichia coli type II DNA topoisomerases. Antimicrob Agents Chemother 1996; 40: 2714-20
15. Pan XS, Fisher LM. Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones. Antimicrob Agents Chemother 1997; 41: 471-4
16. Pan XS, Fisher LM. DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae. Antimicrob Agents Chemother 1998; 42: 2810-6
17. Pan XS, Fisher LM. Streptococcus pneumoniae DNA gyrase and topoisomerase IV: overexpression, purification, and differential inhibition by fluoroquinolones. Antimicrob Agents Chemother 1999; 43: 1129-36
18. Morrissey I, George JT. The unique equipotency of sitafloxacin against topoisomerase IV and DNA gyrase from Streptococcus pneumoniae. Abstract from the 6th International Symposium on New Quinolones; 1998 Nov 15-17: Denver, USA
19. Cole ST, Brosch R, Parkhill J, et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998; 393: 537-44
20. Fraser CM, Norris SJ, Weinstock GM, et al. Complete genome sequence of Treponema pallidum, the syphilis spirochete. Science 1998; 281: 375-88
21. Tomb JF, White O, Kerlavage AR, et al. The complete genome sequence of the gastric pathogen Helicobacter pylori. Nature 1997; 388: 539-47
22. Berger JM, Gamblin SJ, Harrison SC, et al. Structure and mechanism of DNA topoisomerase II. Nature 1996; 379: 225-32
23. Cabral JH, Jackson AP, Smith CV, et al. Crystal structure of the breakage-reunion domain of DNA gyrase. Nature 1997; 388: 903-6
24. Lewis RJ, Singh OM, Smith CV, et al. Crystallization of inhibitor complexes of an N-terminal 24 kDa fragment of the DNA gyrase B protein. J Mol Biol 1994; 241: 128-30
25. Berger JM. Type II DNA topoisomerases. Curr Opin Struct Biol 1998; 8: 26-32
26. Willmott CJ, Maxwell A. A single point mutation in the DNA gyrase A protein greatly reduces binding of fluoroquinolones to the gyrase-DNA complex. Antimicrob Agents Chemother 1993; 37: 126-7
27. Fass D, Bogden CE, Berger JM. Quaternary changes in topoisomerase II may direct orthogonal movement of two DNA strands. Nat Struct Biol 1999; 6: 322-6
28. Shen LL, Kohlbrenner WE, Weigl D, et al. Mechanism of quinolone inhibition of DNA gyrase. Appearance of unique norfloxacin binding sites in enzyme-DNA complexes. J Biol Chem 1989; 264: 2973-8
29. Marians KJ, Hiasa H. Mechanism of quinolone action - a drug-induced structural perturbation of the DNA precedes strand cleavage by topoisomerase IV. J Biol Chem 1997; 272: 9401-9
30. Critchlow SE, Maxwell A. DNA cleavage is not required for the binding of quinolone drugs to the DNA gyrase - DNA complex. Biochemistry 1996; 35: 7387-93
31. Kampranis SC, Maxwell A. Conformational changes in DNA gyrase revealed by limited proteolysis. J Biol Chem 1998; 273: 22606-14
32. Kampranis SC, Maxwell A. The DNA gyrase-quinolone complex -ATP hydrolysis and the mechanism of DNA cleavage. J Biol Chem 1998; 273: 22615-26
33. Scheirer KE, Higgins NP. The DNA cleavage reaction of DNA gyrase -comparison of stable ternary complexes formed with enoxacin and CcdB protein. J Biol Chem 1997; 272: 27202-9
34. Khodursky AB, Cozzarelli NR. The mechanism of inhibition of topoisomerase IV by quinolone antibacterials. J Biol Chem 1998; 273: 27668-77
35. Hiasa H, Yousef DO, Marians KJ. DNA strand cleavage is required for replication fork arrest by a frozen topoisomerase-quinolone-DNA ternary complex. J Biol Chem 1996; 271: 26424-9
36. Drlica K, Engle EC, Manes SH. DNA gyrase on the bacterial chromosome: possibility of two levels of action. Proc Natl Acad Sci USA 1980; 77: 6879-83
37. Huang WM, Libbey JL, Van der Hoeven P, et al. Bipolar localization of Bacillus subtilis topoisomerase IV, an enzyme required for chromosome segregation. Proc Natl Acad Sci USA 1998; 95: 4652-7
38. Willmott CJ, Critchlow SE, Eperon IC, et al. The complex of DNAgyrase and quinolone drugs with DNA forms a barrier to transcription by RNA polymerase. J Mol Biol 1994; 242: 351-63